|
Canada-0-EXPLOSIVES Azienda Directories
|
Azienda News:
- Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
DICE Therapeutics, Inc is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas
- Eli Lilly rolls the dice, axing psoriasis prospect and pivoting to . . .
Eli Lilly has dropped (PDF) the lead candidate from its $2 4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule
- Lilly bets $2. 4bn on Dice’s immune disease platform
Eli Lilly has struck a $2 4 billion deal to buy Dice Therapeutics and its drug discovery and development platform for oral, small molecule therapies for immunological diseases The big pharma
- DICE Therapeutics 2026 Company Profile: Valuation, Investors . . .
Information on acquisition, funding, cap tables, investors, and executives for DICE Therapeutics Use the PitchBook Platform to explore the full profile
- Lilly to Acquire DICE for $2. 4B, Expanding Immunology Pipeline
Eli Lilly has agreed to acquire DICE Therapeutics for $2 4 billion, the companies said today, in a deal designed to expand the buyer’s immunology pipeline with two clinical-stage programs based
- Lilly to buy oral immune drug developer Dice Therapeutics for $2. 4B
Eli Lilly has agreed to buy Dice Therapeutics for about $2 4 billion in a deal that gives the pharmaceutical giant a promising oral autoimmune disease drug in clinical testing
- Dice Therapeutics - Crunchbase Company Profile Funding
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas
- Eli Lilly Acquires Immunology Firm DICE Therapeutics for $2. 4B
Eli Lilly today announced it is buying DICE Therapeutics for $2 4 billion DICE applies its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including IL-17 inhibitors, to treat chronic autoimmune and inflammatory diseases
- Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
DICE Therapeutics, Inc is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in
- Lillys Bold Bet on IL-17: A $2. 4 Billion Acquisition of Dice . . .
The company recently acquired Dice Therapeutics for an upfront payment of $2 4 billion, with hopes that this strategic move will enhance the effectiveness of its existing arsenal against these conditions
|
|